3B Pharmaceuticals AG
3B Pharmaceuticals is a German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology applications.
About
3B Pharmaceuticals GmbH (3BP) is a privately held German biotechnology company specializing in the development of targeted radiopharmaceutical drugs and diagnostics for treating oncology indications with high unmet medical need. 3BP uses its proprietary peptide discovery and optimization technology platform to develop innovative compounds that enable precise delivery of diagnostic and therapeutic radioisotopes to tumors. The company’s mission is to advance the standard of care in precision oncology through innovative nuclear medicine solutions. 3BP has built a broad pipeline from hit identification to early clinical development, focusing on a theragnostic approach in which diagnostic imaging is used to identify patients likely to respond to radiopharmaceutical therapies. The technology platform and expertise enable the company to address both established and novel cancer drug targets, developing next-generation therapeutics and imaging agents.
Products & Services
- FAP-2286: FAP-targeted peptide radioligand therapy and imaging agent (in collaboration/licensed to Novartis)
- 3BP-227 / FPI-2059 / IPN01087: NTR1-targeted radiopharmaceutical (neurotensin receptor 1, for pancreatic and other cancers)
- 3BP-4961: FAP-targeted SPECT imaging agent (for solid and benign tumors)
- 3BP-5201: FAP-targeted PET imaging agent (licensed to RefleXion Medical for SCINTIX biology-guided radiotherapy)
- 3BP-3775: GIP receptor-targeted radiopharmaceutical for neuroendocrine tumors
- 3BP-4452 / DPI-4452 / Debio 0228 / ITM-91: CAIX-targeted radiopharmaceutical, licensed to Debiopharm and ITM Isotope Technologies Munich SE
- 3BP-6146: uPAR-targeted agent for breast and brain cancer imaging and treatment
- 3BP-6121: P-cadherin-targeted theranostic agent for breast, ovarian, and colorectal cancer
- Clinical trials (e.g., LuMIERE study with FAP-2286, NCT04939610)
- Development of targeted radiotherapeutic and diagnostic radiopharmaceuticals
- Peptide and peptidomimetic discovery and optimization platform
- Contract research and development collaborations
Use Cases & Case Studies
- Radiopharmaceutical precision therapies for cancer treatment with minimized damage to healthy tissue
- Clinical trials in patients with solid tumors using FAP-2286 and other compounds
- Development and validation of imaging and companion diagnostics to select likely responders for radiopharmaceutical therapy
Partnerships & Collaborations
- Novartis (exclusive licensing agreement for FAP-targeting peptide technology and PSMA radioligand therapy program)
- Debiopharm International SA (exclusive worldwide license for CAIX-targeted radiopharmaceutical program; Debio 0228)
- ITM Isotope Technologies Munich SE (license from Debiopharm for CAIX program)
- Clovis Oncology (collaboration and license agreement for FAP-targeted radiopharmaceutical program)
- ARTBIO (licensing and research partnership for first-in-class alpha radioligand therapy)
- RefleXion Medical (exclusive licensing agreement for FAP-targeting molecule for SCINTIX radiotherapy)
- TetraKit Technologies (strategic collaboration in targeted alpha radioligand therapy development)
- Boehringer Ingelheim (drug discovery collaboration)
- Ipsen (licensing agreement for novel radiopharmaceuticals in oncology)
- KNAUER (collaboration on affinity purification process for antibodies)
- Sovicell (collaboration on plasma protein binding analysis)
Awards & Recognition
- Platinum Sponsor of the 6th Theranostic World Congress (2022)